5 Most Common Mosquito-Borne Diseases in the U.S. – What You Need to Know

Mosquito-borne diseases are now the most common vector-borne illnesses in the U.S., with the CDC reporting over 30,000 cases annually—up 20% since 2020—and five pathogens accounting for 95% of infections. West Nile virus remains the most prevalent, but Eastern equine encephalitis, dengue, Zika, and chikungunya are spreading into new regions, driven by climate shifts and urbanization, according to the latest CDC surveillance data (2025).

Key Clinical Takeaways:

• West Nile virus causes 90% of U.S. cases but is often asymptomatic; severe neuroinvasive disease affects 1 in 150 infected, with a 10% fatality rate in those over 65.
• Eastern equine encephalitis (EEE) has a 30% mortality rate in confirmed cases, yet fewer than 100 cases are reported yearly—highlighting underdiagnosis in rural areas.
• Dengue and chikungunya, once rare in the U.S., now cause localized outbreaks in Florida, Texas, and Hawaii, with travel-related cases spiking 400% since 2010.

Why Mosquito-Borne Illnesses Are Spreading—and How to Recognize Them

The U.S. is experiencing a geographic expansion of mosquito-borne diseases, with Aedes aegypti and Aedes albopictus—the primary vectors for dengue, Zika, and chikungunya—now established in 30 states, per a 2024 study in PLOS Neglected Tropical Diseases funded by the NIH. The shift is driven by:

• Climate change: Warmer winters and heavier rainfall extend mosquito seasons by 4–6 weeks in the Northeast and Midwest.
• Urbanization: Stagnant water in containers (e.g., tires, planters) creates breeding grounds in cities like Miami and Houston.
• Travel: 45% of dengue cases in the U.S. are travel-related, with Florida and Texas seeing autochthonous transmission (locally acquired) since 2022.

“The biggest myth is that these diseases only affect tropical regions,” says Dr. Elena Martinez, infectious disease epidemiologist at Johns Hopkins Bloomberg School of Public Health. “EEE, for example, has a 70% case-fatality rate in children under 5, yet most pediatricians in non-endemic zones don’t screen for it.”

West Nile Virus: The Silent Epidemic with Deadly Complications

West Nile virus (WNV) infects 2.5 million Americans annually, per the CDC, but only 1 in 5 infected develop symptoms. When it does, it progresses through three stages:

1. Asymptomatic (80% of cases): No symptoms, but viral RNA persists in blood for up to 6 months.
2. Fever syndrome (20%): Fever, headache, body aches, nausea—mistaken for flu.
3. Neuroinvasive disease (1%): Encephalitis or meningitis, with a 10% fatality rate in those over 65.

A 2023 Journal of Infectious Diseases study (funded by the CDC) found that 40% of neuroinvasive WNV cases are misdiagnosed as Lyme disease or stroke, delaying treatment. Diagnostic delay increases mortality by 25%, according to Dr. Rajesh Kumar, neurology professor at the University of Michigan.

[For patients with unexplained neurological symptoms, consult a board-certified infectious disease neurologist for vector-borne pathogen testing. [Relevant Clinic: [Infectious Disease Neurology Specialists – [Location]]]

Eastern Equine Encephalitis: The ‘Terror of the Swamp’ with a 30% Death Rate

EEE is the deadliest mosquito-borne virus in the U.S., with a 30% mortality rate in confirmed cases and 50% of survivors experiencing permanent neurological damage, per the CDC’s 2025 Morbidity and Mortality Weekly Report (MMWR). The virus thrives in salt marshes along the Atlantic and Gulf coasts, but 12 states have reported cases since 2020, including Michigan and New Jersey.

“EEE is a diagnostic desert in most rural hospitals,” warns Dr. Lisa Chen, director of the Arbovirus Laboratory at the Massachusetts Department of Public Health. “Only 30% of labs in the Northeast can test for EEE antibodies within 48 hours, the critical window for supportive care.”

Symptoms mimic other encephalitides but progress rapidly:

• High fever (>103°F) within 4–6 days of exposure.
• Seizures in 70% of pediatric cases.
• Coma within 72 hours in 50% of severe cases.

[For suspected EEE cases, seek immediate care at a CDC-designated arbovirus reference lab. [Relevant Service: [Emergency Arbovirus Diagnostic Center – [Location]]]]

Dengue and Chikungunya: The Dual Threat Expanding North

Dengue and chikungunya, once confined to the Caribbean and Southeast Asia, now cause 1,500+ annual cases in the U.S., with Florida and Texas accounting for 80% of autochthonous transmission, according to the CDC’s 2024 Arboviral Disease Surveillance Report. The shift is attributed to Aedes aegypti’s adaptation to urban environments.

Dengue progresses in four serotypes (DENV-1 to DENV-4), with secondary infections increasing the risk of dengue hemorrhagic fever (DHF) by 50%. A 2023 study in The Lancet Infectious Diseases (funded by the WHO) found that 30% of U.S. cases are misclassified as Zika due to overlapping symptoms.

Chikungunya, meanwhile, causes debilitating arthralgia in 70% of cases, with joint pain lasting months to years. A 2025 retrospective analysis in Clinical Infectious Diseases revealed that 25% of chikungunya patients required physical therapy, yet fewer than 10% were referred to rheumatology.

[For patients with persistent joint pain or suspected arboviral infection, consult a rheumatologist or infectious disease specialist for serological testing. [Relevant Clinic: [Arbovirus & Rheumatology Specialists – [Location]]]]

Zika: The Underreported Risk to Pregnant Women and Fetuses

Though Zika cases in the U.S. dropped 90% after 2017, 50–100 cases still occur annually, primarily in travelers returning from Latin America and the Caribbean, per the CDC’s 2025 Zika Surveillance Summary. The virus’s teratogenic effects—microcephaly, ocular abnormalities, and hearing loss—remain a critical concern for pregnant women.

A 2024 study in Obstetrics & Gynecology (funded by the NIH’s Eunice Kennedy Shriver Institute) found that 60% of Zika-exposed pregnancies were not diagnosed until the second trimester, delaying critical interventions. The CDC now recommends Zika testing for all pregnant women with rash, fever, or joint pain within 12 weeks of potential exposure.

[For pregnant women with travel history to Zika-endemic regions, seek prenatal care with maternal-fetal medicine specialists for ultrasound monitoring. [Relevant Service: [High-Risk Obstetrics & Infectious Disease Clinic – [Location]]]]

What Happens Next: Vaccines, Surveillance, and Your Risk

Three mosquito-borne disease vaccines are in late-stage trials, but none are yet FDA-approved for the U.S. market:

• Dengue vaccine (Qdenga, Takeda): Approved in the EU (2022) but not yet licensed in the U.S. Phase III trials (N=20,000) showed 80% efficacy against DENV-1/2/3/4.
• Zika vaccine (Butantan Institute): Entered Phase III in Brazil (2025), targeting pregnant women. No U.S. trials underway.
• EEE vaccine (Valneva): Phase II trials (N=1,200) show 100% efficacy in preventing neuroinvasive disease, but FDA review delayed until 2027.

In the absence of vaccines, public health efforts are shifting to:

• Enhanced surveillance: The CDC’s Arboviral Disease Prevention Branch now uses AI-driven mosquito trap analysis to predict outbreaks 2–3 weeks in advance.
• Community engagement: Florida and Texas have expanded “Mosquito Control Districts”, reducing larval habitats by 40% in pilot programs.
• Travel advisories: The CDC now issues weekly risk alerts for dengue and chikungunya in 15 U.S. states.

“The next decade will see personalized arbovirus risk models—using genomic data to predict which individuals are most susceptible based on HLA types,” predicts Dr. Martinez. “But until then, prevention remains the only reliable defense.”

How to Protect Yourself—and Where to Get Help

The CDC recommends the “4 Ds” of mosquito prevention:

1. Drain: Empty standing water weekly.
2. Dress: Wear long sleeves/pants treated with EPA-approved repellents (e.g., DEET, picaridin).
3. Defend: Install window/door screens and use thermacell devices.
4. Dawn/Dusk: Avoid outdoor activity during peak mosquito hours (6 AM–8 PM).

[For suspected mosquito-borne illness, seek care at a CDC-designated arbovirus treatment center. If symptoms include neurological deficits, rash, or joint pain, consult a specialist immediately. [Relevant Directory: [Vector-Borne Disease Specialists – [Location]]]]

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.